Vir’s George Scangos teams up with his former colleagues at Biogen to press fast-forward on antibody programs for coronavirus
Vir CEO George Scangos is in hot pursuit of some antibodies that can combat coronavirus. And he’s turned to one big shop he knows well to cover the manufacturing end of that strategy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.